Pamela Rivero-García

Pamela Rivero-García

Auto-generated profile, based on publicly available information

Pamela Rivero-García

Affiliation Department of Medical Genetics, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 May 2024 in Heliyon
Verified
Journal Article
Open access
PRPamela Rivero-García
Pamela Rivero-García
YCYanin Chavarri-Guerra
Yanin Chavarri-Guerra
JOJosé Luis Rodríguez Olivares
José Luis Rodríguez Olivares
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
JHJosef Herzog
Josef Herzog
JAJazmín Arteaga-Vázquez
Jazmín Arteaga-Vázquez
Lynch syndrome (LS) is the most frequent cancer predisposition syndrome affecting the colon and rectum. A pathogenic variant (PV) disrupting one of the mismatch repair (MMR) genes is responsible for the disease. The spectrum of tumors in LS is heterogeneous and includes cancer of the colon and rectum (CRC), endometrium, ovaries, stomach, small bowel, urinary tract, bladder, pancreas, and skin. Knowledge of the phenotypic variation of patients with LS, the type and frequency of PVs, and cascade testing studies in the Latin American population is limited. The present study aims to recognize the PVs in MMR genes, describe the phenotype in Mexican-Mestizo patients and their relatives, and identify the acceptance rate of cascade testing of relatives at risk. We included 40 carriers of a MMR gene PV and 142 relatives that developed a LS-related neoplasm. Patients’ clinical data, number, and type of malignancies were obtained from their medical records. Amsterdam I-II, Bethesda criteria, and PREMM5® predictive model score were estimated. Available immunohistochemistry (IHC) reports were analyzed. Relatives at risk were determined from index cases pedigrees. The distribution of MMR gene mutations among 40 probands was: MLH1 (67.5 %), MSH2 (22.5 %), MSH6 (7.5 %), and PMS2 (2.5 %). Out of the 182 LS cases, 58 % exhibited the LS phenotype before age 50. The most common tumor was CRC, followed by endometrial cancer in women and gastric cancer in males. We found a 90.0 % concordance between the IHC and germline PV. The most frequent PV in our sample was MLH1 c.676C > T, occurring in 1/6 index cases. All probands disclosed their molecular test result to their family. Out of the 451 asymptomatic relatives at risk, 28.2 % underwent germline testing. Our results highlight the importance of conducting germline genetic studies in LS since it allows the establishment of appropriate cancer screening, risk-reducing measures, and genetic cascade testing among relatives at risk. Interestingly, we observed a significantly higher prevalence of the c.676C > T variant in MLH1, probably a singular characteristic of the Mexican-Mestizo population. New strategies to facilitate accurate communication between index cases and relatives should be implemented to improve the cascade testing acceptance rate.

23 June 2023 in Clinical Case Reports
Verified
Journal Article
Open access
PRPamela Rivero‐García
Pamela Rivero‐García
ICIsabel del Carmen Campuzano‐Estrada
Isabel del Carmen Campuzano‐Estrada
JHJorge Humberto Hernandez‐Felix
Jorge Humberto Hernandez‐Felix
Key Clinical Message: Noonan syndrome with multiple lentigines (NSML) is a rare RASopathy caused by pathogenic variants (PV) predominantly in PTPN11 gene. We report a 54‐year‐old male with apical hypertrophic cardiomyopathy, who was diagnosed with NSML due to his short stature, multiple lentigines, winged neck, pectus excavatum, and a heterozygous PV in PTPN11 c.836A > ¡G.

23 October 2023 in Clinical Case Reports
Verified
Journal Article
Open access
TKTamara N. Kimball
Tamara N. Kimball
PRPamela Rivero‐García
Pamela Rivero‐García
BGBernardo Pérez González
Bernardo Pérez González
ARAlfredo Adolfo Reza‐Albarrán
Alfredo Adolfo Reza‐Albarrán
Key Clinical Message: Diastrophic dysplasia (DTD) is caused by biallelic pathogenic variants in the SLC26A2 gene. We report the case of a 49‐year‐old female with DTD and esophageal stenosis. This broadens the phenotypic spectrum in adult patients with DTD and raises awareness of extra‐skeletal manifestations that could develop in later stages of life.

4 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJosé Luis Rodríguez-Olivares
José Luis Rodríguez-Olivares
DADione Aguilar-Y-Méndez
Dione Aguilar-Y-Méndez
TKTamara N. Kimball
Tamara N. Kimball
PRPamela Rivero-García
Pamela Rivero-García
JRJavier Rios-Valencia
Javier Rios-Valencia
YCYanin Chávarri-Guerra
Yanin Chávarri-Guerra
Background: All individuals with colorectal cancer (CRC) should undergo genetic cancer risk assessment given its implications for personalized treatment, surveillance, risk-reduction strategies, and cascade testing. Universal screening using immunohistochemistry (IHC) for mismatch repair (MMR) proteins in tumor tissue, when combined with clinical criteria, is essential for identifying individuals at higher risk for carrying germline pathogenic variants (PVs) in resource limited countries. Patients and Methods: The spectrum of PVs in cancer susceptibility genes was characterized using NGS multigene panel assays among selected patients with CRC at two centers in Mexico. Germline genetic testing was used as the reference standard to evaluate the diagnostic accuracy of the referral criteria. Results: From September 2018 to October 2024, 208 patients were enrolled. The median age at diagnosis was 45.0 years; 52.4% were women, 48.6% had deficient-MMR CRC, and 38.0% reported family history of CRC. Germline PVs were identified in 32.2% (n = 67); of these, 77.6% (n = 52) had Lynch syndrome (30 MLH1 , 14 MSH2 , 6 MSH6 , and 2 PMS2 ), while 22.4% (n = 15) harbored PVs in other genes (4 ATM , 3 BRCA1 , 3 CHEK2 , 2 TP53 , 1 BRCA2 , 1 BRIP1 , and 1 PALB2 ). Additionally, one individual harbored a monoallelic PV in MUTYH . The Amsterdam II criteria demonstrated the highest specificity (Sensitivity 56.0%, Specificity 91.9%), while the revised Bethesda criteria (Sensitivity 98.1%, Specificity 19.9%) and IHC for MMR proteins (Sensitivity 91.2%, Specificity 68.7%) exhibited high sensitivity. The area under the ROC curve for PREMM5 was 0.822 (95% CI 0.746–0.898). Conclusion: PREMM5, Revised Bethesda criteria and IHC for MMR proteins effectively prioritized patients eligible for germline genetic testing in resource-limited settings. The performance of PREMM5 in this Mexican cohort was comparable to findings reported in validation studies within other populations. Considering the spectrum of PVs identified, employing a multigene panel test is recommended for Mexican patients with CRC.

2 December 2024 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
TKTamara N. Kimball
Tamara N. Kimball
PRPamela Rivero‐García
Pamela Rivero‐García
EAEduardo Argaiz
Eduardo Argaiz
JGJorge Eduardo Gaytan‐Arocha
Jorge Eduardo Gaytan‐Arocha
NUNorma Ofelia Uribe Uribe
Norma Ofelia Uribe Uribe
JSJuan José Morales Suárez
Juan José Morales Suárez
Introduction: Fabry disease (FD) is a rare lysosomal type 3 disorder with an X‐linked inheritance pattern caused by pathogenic variants in the GLA gene. This study aimed to describe the genotype and phenotype of 52 Mexican patients with FD.Methods: We included 12 patients with clinical and molecular diagnosis of FD treated at our institution and 40 FD Mexican patients already reported in the literature.Results: The most frequent manifestations were acroparesthesias (71.2%), hypohidrosis or anhidrosis (48.1%), heat intolerance (46.2%), and proteinuria (42.3%). Renal and neurological manifestations were more prevalent in males than females. Cardiac involvement included hypertrophic cardiomyopathy and Wolf–Parkinson–White arrhythmia. Cornea verticillata was seen in 14 patients (26.9%) and angiokeratomas in 15 (28.8%). We identified 14 variants in the GLA gene in Mexican patients with FD. We found a novel variant GLA c.122C>G that causes an atypical FD phenotype with predominantly neurological involvement in two unrelated patients, one of them with a forthright clinical and radiological overlap of Multiple Sclerosis and normal biological biomarkers, thus requiring a renal biopsy that helped confirm the diagnosis of FD.Conclusions: The genotype and phenotype of Mexican patients with FD are similar to other populations. Atypical phenotype of FD, such as the one associated with the novel variant c.122C>G, can be a diagnostic challenge, as it can be mixed up with MS. Our findings confirm the limitations of noninvasive diagnostic methods and the necessity of the renal biopsy when the clinical suspicion of FD is high.